News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,249 Results
Type
Article (134)
Press Release (1115)
Section
Business (441)
Career Advice (19)
Deals (44)
Drug Development (218)
FDA (45)
Job Trends (17)
News (767)
Policy (107)
Tag
Africa (2)
Alliances (36)
Approvals (45)
Arizona (1)
Asia (13)
Australia (1)
Best Places to Work (10)
C2C Services and Suppliers (6)
California (2)
Career advice (13)
Clinical research (188)
COVID-19 (1)
Diagnostics (3)
Earnings (200)
Europe (503)
Events (252)
Executive appointments (1)
FDA (45)
GLP-1 (1)
Government (17)
Healthcare (19)
Hotbed/Location (593)
Infectious disease (1)
Inflation Reduction Act (1)
Interviews (5)
IPO (20)
Job creations (7)
Job search strategy (11)
Layoffs (1)
Legal (18)
Massachusetts (4)
Medical device (2)
Medtech (2)
Mergers & acquisitions (24)
NextGen Class of 2024 (7)
Non-profit (3)
North Carolina (1)
Opinion (3)
People (182)
Phase I (47)
Phase II (59)
Phase III (88)
Pipeline (1)
Postmarket research (29)
Preclinical (10)
Radiopharmaceuticals (1)
Real estate (7)
Regulatory (77)
Research institute (1)
Resumes & cover letters (4)
South America (1)
Southern California (2)
Special edition (1)
Startups (12)
United States (8)
Date
Last 365 days (52)
2024 (31)
2023 (73)
2022 (80)
2021 (94)
2020 (104)
2019 (85)
2018 (78)
2017 (56)
2016 (62)
2015 (62)
2014 (55)
2013 (44)
2012 (58)
2011 (74)
2010 (56)
1,249 Results for "alkermes".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alkermes to Participate in Two Upcoming June 2024 Investor Conferences
Alkermes plc announced that management will participate in fireside chat presentations at two upcoming investor conferences.
May 29, 2024
·
1 min read
Business
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc reported financial results for the first quarter of 2024.
May 1, 2024
·
14 min read
Policy
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk.
May 2, 2024
·
3 min read
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Alkermes plc announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies, taking place June 1-5, 2024 in Houston.
May 28, 2024
·
5 min read
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Alkermes plc announced the presentation of research related to its psychiatry franchise products—LYBALVI® and ARISTADA® —at four scientific conferences this spring.
May 14, 2024
·
20 min read
Business
Alkermes to Report First Quarter Financial Results on May 1, 2024
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company’s first quarter financial results.
April 17, 2024
·
1 min read
Genetown
Alkermes’ Commitment to Integrity and Compliance
Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in the markets in which we operate and to maintaining a strong culture of compliance.
December 18, 2023
·
12 min read
Business
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company’s Board of Directors (the Board).
March 7, 2024
·
4 min read
Business
Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios
Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.
March 11, 2024
·
3 min read
·
Greg Slabodkin
Drug Development
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.
April 24, 2024
·
5 min read
1 of 125
Next
